PHAL: Net loss deepened in 2025 as focus shifts to international funding and clinical trial execution

About this update from Pharmalundensis Ab

Advanced drug and cleantech projects progressed, but net loss widened to -7.1 MSEK in 2025. Delisting from Spotlight aims to attract international investors and secure 30–60 MSEK for clinical trials, with significant funding and debt repayment risks remaining.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmalundensis Ab